Please login to the form below

Not currently logged in
Email:
Password:

Prostate cancer treatment market to treble to £8.2bn by 2023

But GlobalData predict growth could be hampered by patent loss for Zytiga

prostate cancerThe global treatment market value for prostate cancer is to treble from $2.6bn in 2013 to an estimated $8.2bn by 2023, according to research by GlobalData.

The research and consulting firm's latest report suggests that the increase, which will occur across the nine major markets - the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and Canada – and is expected to be driven by a rapidly ageing population, the introduction of nine premium-priced therapies and the proposed label extensions for Zytiga and Xtandi the treatment of hormone-sensitive prostate cancer.

The analyst noted that the primary driver of growth across the major markets for the treatment of prostate cancer will be the label extension Xtandi.

Raksha Mudbhary, GlobalData's senior analyst covering oncology, commented: “Xtandi's safety and efficacy garnered a favorable impression from key opinion leaders, and its use in multiple prostate cancer patient segments ensures that it will be the market-leading drug in this therapy area by 2016.

“GlobalData forecasts that sales of Xtandi will grow to $3.8 billion by 2023, at a CAGR of 24%, accounting for an impressive 46% of total branded drug sales in the prostate cancer space."

Although the outlook is positive for the treatment sector, other factors may stunt growth including the loss of patent protection for Zytiga, the leading drug in the prostate cancer therapeutics market in 2013.

Mudbhary continued: “Zytiga is anticipated to lose key US patent protection in December 2016. Although there is some uncertainty regarding the timing of Zytiga generics entering the US market, the resulting loss of branded sales will restrict growth during the latter part of the forecast period.”

Article by
Kirstie Pickering

1st May 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics